STAT+: FDA pushing non-opioid path for chronic pain

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning. Today, we note that psychedelics are suddenly a hot topic for larger pharmaceutical companies, dissect Patrick Soon-Shiong’s claims on his lung cancer drug, and more.

Pharma is quickly warming to psychedelics

AbbVie’s $1.2 billion move to buy Gilgamesh’s psychedelic candidate is the first time a traditional drugmaker has snapped up an investigational psychedelic — a milestone that analysts say could trigger a wave of follow-on deals, STAT’s Olivia Goldhill writes.

Continue to STAT+ to read the full story…